A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
BACKGROUND: In two of three phase 3 trials, pirfenidone, an oral antifibrotic therapy, reduced disease progression, as measured by the decline in forced vital capacity (FVC) or vital capacity, in patients with idiopathic pulmonary fibrosis; in the third trial, this end point was not achieved. We sought to confirm the beneficial effect of pirfenidone on disease progression in such patients. METHODS: In this phase 3 study, we randomly assigned 555 patients with idiopathic pulmonary fibrosis to receive either oral pirfenidone (2403 mg per day) or placebo for 52 weeks. The primary end point was the change in FVC or death at week 52. Secondary end points were the 6-minute walk distance, progression-free survival, dyspnea, and death from any cause or from idiopathic pulmonary fibrosis. RESULTS: In the pirfenidone group, as compared with the placebo group, there was a relative reduction of 47.9% in the proportion of patients who had an absolute decline of 10 percentage points or more in the percentage of the predicted FVC or who died; there was also a relative increase of 132.5% in the proportion of patients with no decline in FVC (P<0.001). Pirfenidone reduced the decline in the 6-minute walk distance (P=0.04) and improved progression-free survival (P<0.001). There was no significant between-group difference in dyspnea scores (P=0.16) or in rates of death from any cause (P=0.10) or from idiopathic pulmonary fibrosis (P=0.23). However, in a prespecified pooled analysis incorporating results from two previous phase 3 trials, the between-group difference favoring pirfenidone was significant for death from any cause (P=0.01) and from idiopathic pulmonary fibrosis (P=0.006). Gastrointestinal and skin-related adverse events were more common in the pirfenidone group than in the placebo group but rarely led to treatment discontinuation. CONCLUSIONS: Pirfenidone, as compared with placebo, reduced disease progression, as reflected by lung function, exercise tolerance, and progression-free survival, in patients with idiopathic pulmonary fibrosis. Treatment was associated with an acceptable side-effect profile and fewer deaths. (Funded by InterMune; ASCEND ClinicalTrials.gov number, NCT01366209.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Idiopathic pulmonary fibrosis (IPF), the prototype of fibrotic ILDs, carries a prognosis of 3–5 years survival after diagnosis when untreated. Two anti-fibrotic medications (nintedanib and pirfenidone) have been shown to reduce the rate of forced vital capacity (FVC) decline and slow disease progression in patients with a definite usual interstitial pneumonia (UIP) pattern and with a probable UIP pattern on high resolution CT (HRCT).(191–193)”
From Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation. (2021) · cites this paper as [191]
In the citing paper
“However, both have significant adverse effects and neither completely arrest the decline in lung function.”
From Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF) (2024) · cites this paper as [13]
In the citing paper
“In three trials with doses that reached 2403 mg/day, pirfenidone effectively reduced FVC decline although had variable reductions in overall mortality and IPF-related mortality [12,13].”
From Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF) (2024) · cites this paper as [13]
In the citing paper
“Reported adverse events in the present trial were generally acceptable and largely consistent with events previously reported by participants in the placebo arms of randomized controlled trials in IPF [45,46].”
From Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study (2019) · cites this paper as [45]
In the citing paper
“FVC is the gold-standard metric for assessing the lung function of patients with IPF and response to therapeutic intervention33–35.”
From A generative AI-discovered TNIK inhibitor for idiopathic pulmonary fibrosis: a randomized phase 2a trial (2025) · cites this paper as [35]
9 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Miller, M. R., Hankinson, J., Brusasco, V., Burgos, F., Casaburi, R., Coates, A., Crapo, R., Enright, P., van der Grinten, C. P. M., Gustafsson, P., et al. (2005) · European Respiratory Journal · doi:10.1183/09031936.05.00034805 · Cited by 15,627
Raghu, G., Collard, H. R., Egan, J. J., Martinez, F. J., Behr, J., Brown, K. K., Colby, T. V., Cordier, J.-F., Flaherty, K. R., Lasky, J. A., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2009-040gl · Cited by 7,186
Self-citationA sharper Bonferroni procedure for multiple tests of significance
HOCHBERG, Y. (1988) · Biometrika · doi:10.1093/biomet/75.4.800 · Cited by 4,829
Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials
Noble, P. W., Albera, C., Bradford, W. Z., Costabel, U., Glassberg, M. K., Kardatzke, D., King, T. E., Lancaster, L., Sahn, S. A., Szwarcberg, J., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60405-4 · Cited by 2,154
Self-citationDouble-blind, Placebo-controlled Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis
Azuma, A., Nukiwa, T., Tsuboi, E., Suga, M., Abe, S., Nakata, K., Taguchi, Y., Nagai, S., Itoh, H., Ohi, M., et al. (2005) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200404-571oc · Cited by 954
Pirfenidone in idiopathic pulmonary fibrosis
Taniguchi, H., Ebina, M., Kondoh, Y., Ogura, T., Azuma, A., Suga, M., Taguchi, Y., Takahashi, H., Nakata, K., Sato, A., et al. (2010) · European Respiratory Journal · doi:10.1183/09031936.00005209 · Cited by 946
Pirfenidone in idiopathic pulmonary fibrosis: Figure 1–
Swigris, J., & Fairclough, D. (2010) · European Respiratory Journal · doi:10.1183/09031936.00071710 · Cited by 799
Self-citationChanges in Clinical and Physiologic Variables Predict Survival in Idiopathic Pulmonary Fibrosis
Collard, H. R., King, T. E., Bartelson, B. B., Vourlekis, J. S., Schwarz, M. I., & Brown, K. K. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200211-1311oc · Cited by 764
Self-citationThe Clinical Course of Patients with Idiopathic Pulmonary Fibrosis
Martinez, F. J., Safrin, S., Weycker, D., Starko, K. M., Bradford, W. Z., King, T. E., Flaherty, K. R., Schwartz, D. A., Noble, P. W., Raghu, G., et al. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-142-12_part_1-200506210-00005 · Cited by 622
Self-citationKing, T. E., Albera, C., Bradford, W. Z., Costabel, U., Hormel, P., Lancaster, L., Noble, P. W., Sahn, S. A., Szwarcberg, J., Thomeer, M., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60551-1 · Cited by 531
Self-citation
Cited by
Items 701–800 of 3,965
Li, Z., Shen, Y., Xin, J., Xu, X., Ding, Q., Chen, W., Wang, J., Lv, Y., Wei, X., Wei, Y., et al. (2023) · Phytotherapy Research · doi:10.1002/ptr.7926 · Cited by 56
Hambly, N., Shimbori, C., & Kolb, M. (2015) · Respirology · doi:10.1111/resp.12569 · Cited by 55
Mukherjee, S., Ayaub, E. A., Murphy, J. S., Lü, C., Kolb, M. R. J., Ask, K., & Janssen, L. J. (2015) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2015-0009oc · Cited by 63
Lung-Dominant Connective Tissue Disease
Omote, N., Taniguchi, H., Kondoh, Y., et al. (2015) · CHEST Journal · doi:10.1378/chest.14-3174 · Cited by 55
Idiopathic pulmonary fibrosis: current treatment options and critical appraisal of nintedanib
Wollin, S. L., Bonella, F., & Stowasser, S. (2015) · Drug Design Development and Therapy · doi:10.2147/dddt.s76648 · Cited by 72
Antifibrotic and anticancer action of 5-ene amino/iminothiazolidinones
Kaminskyy, D. V., den Hartog, G. J. M., Wojtyra, M., Lelyukh, M. I., Gzella, A. K., Bast, A., & Lesyk, R. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.02.011 · Cited by 60
Sun, N., Fernandez, I. E., Wei, M., Wu, Y., Aichler, M., Eickelberg, O., & Walch, A. K. (2015) · Histochemistry and Cell Biology · doi:10.1007/s00418-015-1382-7 · Cited by 60
“Pirfenidone was the first drug approved for IPF treatment, initially in the EU and recently in the USA, after it was demonstrated that pirfenidone slowed IPF progression by decreasing FEV1 (forced expiratory volume in 1 s) decline in multiple studies (King et al. 2014; Noble et al. 2011).”
BackgroundTGFβ as a therapeutic target in cystic fibrosis
Kramer, E. L., & Clancy, J. P. (2017) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2018.1406922 · Cited by 60
IL-9 Blockade Suppresses Silica-induced Lung Inflammation and Fibrosis in Mice
Sugimoto, N., Suzukawa, M., Nagase, H., Koizumi, Y., Ro, S., Kobayashi, K., Yoshihara, H., Kojima, Y., Asae, K.-H., Hebisawa, A., et al. (2019) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2017-0287oc · Cited by 63
Jacob, J., Aksman, L., Moğulkoç, N., Procter, A., Gholipour, B., Cross, G., Barnett, J. L., Brereton, C. J., Jones, M. G., van Moorsel, C. H. M., et al. (2020) · Thorax · doi:10.1136/thoraxjnl-2019-213865 · Cited by 61
Effectiveness of Proton Pump Inhibitors in Idiopathic Pulmonary Fibrosis
Tran, T., Assayag, D., Ernst, P., & Suissa, S. (2020) · CHEST Journal · doi:10.1016/j.chest.2020.08.2080 · Cited by 60
Genetic Risk Factors for Idiopathic Pulmonary Fibrosis: Insights into Immunopathogenesis
Michalski, J. E., & Schwartz, D. A. (2021) · Journal of Inflammation Research · doi:10.2147/jir.s280958 · Cited by 67
Detection and Early Referral of Patients With Interstitial Lung Abnormalities
Hunninghake, G. M., Goldin, J. G., Kadoch, M. A., Kropski, J. A., Rosas, I. O., Wells, A. U., Yadav, R., Lazarus, H. M., Abtin, F. G., Corte, T. J., et al. (2021) · CHEST Journal · doi:10.1016/j.chest.2021.06.035 · Cited by 60
Self-citationPatient Registries in Idiopathic Pulmonary Fibrosis
Culver, D. A., Behr, J., Belperio, J. A., Corte, T. J., de Andrade, J. A., Flaherty, K. R., Gulati, M., Huie, T. J., LANCASTER, L. H., Roman, J., et al. (2019) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201902-0431ci · Cited by 58
Self-citationNeighborhood-Level Disadvantage Impacts on Patients with Fibrotic Interstitial Lung Disease
Goobie, G. C., Ryerson, C. J., Johannson, K. A., Schikowski, E., Zou, R. H., Khalil, N., Marcoux, V. S., Assayag, D., Manganas, H., Fisher, J. H., et al. (2022) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202109-2065oc · Cited by 60
Uegami, W., Bychkov, A., Ozasa, M., Uehara, K., Kataoka, K., Johkoh, T., Kondoh, Y., Sakanashi, H., & Fukuoka, J. (2022) · Modern Pathology · doi:10.1038/s41379-022-01025-7 · Cited by 54
Sullivan, D. I., & Ascherman, D. P. (2024) · Current Rheumatology Reports · doi:10.1007/s11926-024-01155-8 · Cited by 66
Asbestosis and environmental causes of usual interstitial pneumonia
Gulati, M., & Redlich, C. A. (2015) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000000144 · Cited by 63
“Pirfenidone is a small-molecule drug whose antifibrotic effects are likely mediated by the transforming growth factor beta pathway [53 ▪ ].”
Yoon, P. O., Park, J. W., Lee, C., Kim, S. H., Kim, H., Ko, Y., Bae, S. J., Yun, S., Park, J. H., Kwon, T., et al. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.693671 · Cited by 57
“Currently only 2 drugs are approved as therapeutic drugs, but they only delay the progress of the disease with improved lung function (43-45).”
BackgroundJo, H. E., Troy, L. K., Keir, G. J., Chambers, D. C., Holland, A. E., Goh, N. S. L., WILSHER, M. L., de Boer, S., Moodley, Y. P., Grainge, C., et al. (2017) · Respirology · doi:10.1111/resp.13146 · Cited by 61
Self-citationWhen to start and when to stop antifibrotic therapies
Torrisi, S. E., Pavone, M., Vancheri, A., & Vancheri, C. (2017) · European Respiratory Review · doi:10.1183/16000617.0053-2017 · Cited by 56
Synergistic role of HSP90α and HSP90β to promote myofibroblast persistence in lung fibrosis
Bellaye, P.-S., Shimbori, C., Yanagihara, T., Carlson, D. A., Hughes, P., Upagupta, C., Sato, S., Wheildon, N., Haystead, T., Ask, K., et al. (2018) · European Respiratory Journal · doi:10.1183/13993003.00386-2017 · Cited by 54
Safer approaches to therapeutic modulation of TGF-β signaling for respiratory disease
Lachapelle, P., Li, M., Douglass, J. A., & Stewart, A. G. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.02.010 · Cited by 56
on behalf of the SEPAR-IPF National Registry, Fernández‐Fabrellas, E., Molina‐Molina, M., Soriano, J. B., Portal, J. A. R., Ancochea, J., Valenzuela, C., & Xaubet, A. (2019) · Respiratory Research · doi:10.1186/s12931-019-1084-0 · Cited by 62
Periera‐Simon, S., Xia, X., Catanuto, P., Coronado, R. E., Kurtzberg, J., Bellio, M. A., Lee, Y., Khan, A., Smith, R. D., Elliot, S. J., et al. (2020) · Respirology · doi:10.1111/resp.13928 · Cited by 55
Self-citationHobbs, S., Chung, J. H., Leb, J. S., Kaproth-Joslin, K. A., & Lynch, D. A. (2021) · Radiology Cardiothoracic Imaging · doi:10.1148/ryct.2021200279 · Cited by 62
Impact of Depression on Patients With Idiopathic Pulmonary Fibrosis
Τzouvelekis, Α., Karampitsakos, Τ., Kourtidou, S., Bouros, E., Tzilas, V., Katsaras, M., Antonou, C., Dassiou, M., & Bouros, D. E. (2020) · Frontiers in Medicine · doi:10.3389/fmed.2020.00029 · Cited by 54
Suzuki, Y., Aono, Y., Kono, M., Hasegawa, H., Yokomura, K., Naoi, H., Hozumi, H., Karayama, M., Furuhashi, K., Enomoto, N., et al. (2020) · Respirology · doi:10.1111/resp.13943 · Cited by 58
Lescoat, A., Varga, J., Matucci‐Cerinic, M., & Khanna, D. (2021) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2021.1923693 · Cited by 57
Tirelli, C., Pesenti, C., Miozzo, M. R., Mondoni, M., Fontana, L., & Centanni, S. (2022) · Diagnostics · doi:10.3390/diagnostics12123107 · Cited by 58
“Two drugs, nintedanib and pirfenidone, have been approved for the treatment of the disease, since in clinical trials and observational studies they have been shown to slow down the progression of the disease, without, however, being able to stop or cure it [4,5].”
BackgroundKaunisto, J., Kelloniemi, K., Sutinen, E., Hodgson, U., Piilonen, A., Kaarteenaho, R., Mäkitaro, R., Purokivi, M., Lappi-Blanco, E., Saarelainen, S., et al. (2015) · BMC Pulmonary Medicine · doi:10.1186/s12890-015-0074-3 · Cited by 53
CT in Idiopathic Pulmonary Fibrosis: Diagnosis and Beyond
Gruden, J. F. (2016) · American Journal of Roentgenology · doi:10.2214/ajr.15.15674 · Cited by 54
“CT and Clinical Trials Recent treatment trials, including those that led to the approval of pirfenidone and nintedanib for the treatment of IPF, used CT primarily as a diagnostic tool for study entry in patients with CT findings, as specified in Table 1 [67, 68].”
BackgroundMethodEmodin alleviates bleomycin-induced pulmonary fibrosis in rats
Guan, R., Zhao, X., Wang, X., Song, N., Guo, Y., Yan, X., Jiang, L., Cheng, W., & Shen, L. (2016) · Toxicology Letters · doi:10.1016/j.toxlet.2016.10.004 · Cited by 53
Early clinical experiences with nintedanib in three UK tertiary interstitial lung disease centres
Toellner, H., Hughes, G., Beswick, W., Crooks, M. G., Donaldson, C., Forrest, I., Hart, S. P., Leonard, C. T., Major, M., Simpson, A. J., et al. (2017) · Clinical and Translational Medicine · doi:10.1186/s40169-017-0172-3 · Cited by 54
Immunometabolism of pro-repair cells
Singer, B. D., & Chandel, N. S. (2019) · Journal of Clinical Investigation · doi:10.1172/jci124613 · Cited by 54
“The antifibrotic medication pirfenidone attenuates TGF-β signaling (156, 157), and may therefore limit mtDNA damage in fibrotic disorders such as idiopathic pulmonary fibrosis.”
BackgroundProesmans, V. L. J., Drent, M., Elfferich, M., Wijnen, P. A. H. M., Jessurun, N. T., & Bast, A. (2019) · Lung · doi:10.1007/s00408-019-00260-1 · Cited by 52
Tian, L., Gao, J., Garcia, I. M., Chen, H. J., Castaldi, A., & Chen, Y. (2020) · Wiley Interdisciplinary Reviews Developmental Biology · doi:10.1002/wdev.399 · Cited by 58
Salunkhe, S. A., Chitkara, D., Mahato, R. I., & Mittal, A. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.04.003 · Cited by 57
SH2 Domain–Containing Phosphatase-2 Is a Novel Antifibrotic Regulator in Pulmonary Fibrosis
Tzouvelekis, A., Yu, G., Cardenas, C. L. L., Herazo‐Maya, J. D., Wang, R., Woolard, T., Zhang, Y., Sakamoto, K., Lee, H., Yi, J.-S., et al. (2016) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201602-0329oc · Cited by 54
Takei, R., Brown, K. K., Yamano, Y., Kataoka, K., Yokoyama, T., Matsuda, T., Kimura, T., Suzuki, A., Furukawa, T., Fukuoka, J., et al. (2022) · Respirology · doi:10.1111/resp.14245 · Cited by 62
Mackintosh, J. A., Keir, G. J., Troy, L. K., Holland, A. E., Grainge, C., Chambers, D. C., Sandford, D., Jo, H. E., Glaspole, I., WILSHER, M. L., et al. (2024) · Respirology · doi:10.1111/resp.14656 · Cited by 60
Self-citationIdiopathic pulmonary fibrosis in BRIC countries: the cases of Brazil, Russia, India, and China
Richeldi, L., Rubin, A. S., Avdeev, S. N., Udwadia, Z. F., & Xu, Z. (2015) · BMC Medicine · doi:10.1186/s12916-015-0495-0 · Cited by 54
Evaluating the interstitial lung disease multidisciplinary meeting: a survey of expert centres
Jo, H. E., Corte, T. J., Moodley, Y. P., Levin, K., Westall, G. P., Hopkins, P. M.-A., Chambers, D. C., & Glaspole, I. (2016) · BMC Pulmonary Medicine · doi:10.1186/s12890-016-0179-3 · Cited by 57
Self-citationIncreased Expression of CC16 in Patients with Idiopathic Pulmonary Fibrosis
Buendía-Roldán, I., Ruiz, V., Sierra, P., Montes, E., Ramírez, R., Vega, A., Salgado-Aguayo, A. R., Vargas, M. H., Mejía, M. E., Pardo, A., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0168552 · Cited by 53
Tomos, I. P., Tzouvelekis, A., Aidinis, V., Manali, E. D., Bouros, E., Bouros, D. E., & Papiris, S. A. (2017) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2017.1300533 · Cited by 57
Li, H., Yu, H., Zhang, H., Ying, W., Li, D., Ge, Y., Ying, B., Cheng, B., Lian, Q., & Jin, S. (2017) · Scientific Reports · doi:10.1038/srep46754 · Cited by 58
Τzouvelekis, Α., Karampitsakos, Τ., Gomatou, G., Bouros, E., Tzilas, V., Manali, E., Tomos, I. P., Trachalaki, A., Kolilekas, L., Korbila, I. P., et al. (2019) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2019.101880 · Cited by 51
Lung Ultrasound Imaging, a Technical Review
Demi, L., Egan, T. M., & Muller, M. M. (2020) · Applied Sciences · doi:10.3390/app10020462 · Cited by 58
“It could also be an extraordinary tool for the evaluation of the efficacy of novel treatments for pulmonary fibrosis [51,52].”
BackgroundKreuter, M., Wuyts, W. A., Wijsenbeek, M. S., Bajwah, S., Maher, T. M., Stowasser, S., Male, N., Stansen, W., Schoof, N., Orsatti, L., et al. (2020) · Respiratory Research · doi:10.1186/s12931-020-1298-1 · Cited by 60
Self-citationBae, W., Lee, C., Lee, J., Kim, Y. W., Han, K., & Choi, S. M. (2021) · Thorax · doi:10.1136/thoraxjnl-2020-215386 · Cited by 59
Campiani, G., Cavella, C., Osko, J. D., Brindisi, M., Relitti, N., Brogi, S., Saraswati, A. P., Federico, S., Chemi, G., Maramai, S., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00184 · Cited by 66
Salisbury, M. L., Xia, M., Murray, S., Bartholmai, B. J., Kazerooni, E. A., Meldrum, C. A., Martinez, F. J., & Flaherty, K. R. (2016) · Respiratory Medicine · doi:10.1016/j.rmed.2016.07.016 · Cited by 51
Idiopathic Interstitial Pneumonia Associated With Autoantibodies
Collins, B. F., Spiekerman, C. F., Shaw, M. A., Ho, L. A., Hayes, J. M., Spada, C. A., Stamato, C. M., & Raghu, G. (2017) · CHEST Journal · doi:10.1016/j.chest.2017.03.004 · Cited by 54
Matsuda, T., Taniguchi, H., Ando, M., Kondoh, Y., Kimura, T., Kataoka, K., Nishimura, K., Nishiyama, O., Sakamoto, K., & Hasegawa, Y. (2017) · Internal Medicine · doi:10.2169/internalmedicine.56.7019 · Cited by 60
Yoon, H., Kim, T. H., Seo, J. B., Lee, S. M., Lim, S., Lee, H. N., Kim, N., Han, M., Kim, D. S., & Song, J. W. (2018) · Respirology · doi:10.1111/resp.13387 · Cited by 54
Interstitial lung disease and obstructive sleep apnea
Khor, Y. H., Ryerson, C. J., Landry, S. A., Howard, M. E., Churchward, T. J., Edwards, B. A., Hamilton, G. S., & Joosten, S. A. (2021) · Sleep Medicine Reviews · doi:10.1016/j.smrv.2021.101442 · Cited by 55
Jouneau, S., Rousseau, C., Léderlin, M., Lescoat, A., Kerjouan, M., Chauvin, P., Paz, D. L., Guillot, S., Oger, E., Vernhet, L., et al. (2022) · Clinical Nutrition · doi:10.1016/j.clnu.2022.05.001 · Cited by 54
Targeting Growth Factor and Cytokine Pathways to Treat Idiopathic Pulmonary Fibrosis
Ma, H., Liu, S., Li, S., & Xia, Y. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.918771 · Cited by 63
The Role of Immune Cells in the Pathogenesis of Idiopathic Pulmonary Fibrosis
Xu, Y., Lan, P., & Wang, T. (2023) · Medicina · doi:10.3390/medicina59111984 · Cited by 68
A new era in idiopathic pulmonary fibrosis: considerations for future clinical trials
Collard, H. R., Bradford, W. Z., Cottin, V., Flaherty, K. R., King, T. E., Koch, G. G., Kolb, M. R. J., Martínez, F. J., Montgomery, B., Raghu, G., et al. (2015) · European Respiratory Journal · doi:10.1183/09031936.00200614 · Cited by 56
Self-citationCognitive function in idiopathic pulmonary fibrosis
Bors, M., Tomic, R., Perlman, D., Kim, H. J., & Whelan, T. P. M. (2015) · Chronic Respiratory Disease · doi:10.1177/1479972315603552 · Cited by 53
Connective tissue disease-related interstitial lung disease
Demoruelle, M. K., Mittoo, S., & Solomon, J. J. (2016) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2016.04.006 · Cited by 55
Lung biopsy in interstitial lung disease: balancing the risk of surgery and diagnostic uncertainty
Cottin, V. (2016) · European Respiratory Journal · doi:10.1183/13993003.01633-2016 · Cited by 57
Antifibrotics in chronic liver disease: tractable targets and translational challenges
Ramachandran, P., & Henderson, N. C. (2016) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(16)30110-8 · Cited by 50
Wallaert, B., Duthoit, L., Drumez, É., Behal, H., Wémeau-Stervinou, L., Chenivesse, C., & Grosbois, J. (2019) · ERJ Open Research · doi:10.1183/23120541.00045-2019 · Cited by 57
Zou, R. H., Kass, D. J., Gibson, K. F., & Lindell, K. O. (2020) · Pulmonary Therapy · doi:10.1007/s41030-019-00108-2 · Cited by 62
Antifibrotic Drug Use in Patients with Idiopathic Pulmonary Fibrosis. Data from the IPF-PRO Registry
Salisbury, M. L., Conoscenti, C., Culver, D. A., Yow, E. S., Neely, M. L., Bender, S. D., Hartmann, N., Palmer, S. M., & Leonard, T. B. (2020) · Annals of the American Thoracic Society · doi:10.1513/annalsats.201912-880oc · Cited by 56
Swigris, J. J., Andrae, D. A., Churney, T., Johnson, N., Scholand, M. B., White, E. S., Matsui, A., Raimundo, K., & Evans, C. J. (2020) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202002-0415oc · Cited by 54
Self-citationDerlin, T., Jäger, B., Jonigk, D. D., Apel, R. M., Freise, J., Shin, H., Weiberg, D., Warnecke, G., Roß, T. L., Wester, H., et al. (2020) · CHEST Journal · doi:10.1016/j.chest.2020.08.2043 · Cited by 57
Qin, W., Zou, J., Huang, Y., Liu, C., Kang, Y., Han, H., Tang, Y., Li, L., Liu, B., Zhao, W., et al. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1824631 · Cited by 63
Treatable traits: a comprehensive precision medicine approach in interstitial lung disease
Khor, Y. H., Cottin, V., Holland, A. E., Inoue, Y., McDonald, V. M., Oldham, J. M., Renzoni, E. A., Russell, A., Strek, M. E., & Ryerson, C. J. (2023) · European Respiratory Journal · doi:10.1183/13993003.00404-2023 · Cited by 57
A comparison of visual and quantitative methods to identify interstitial lung abnormalities
Kliment, C. R., Araki, T., Doyle, T. J., Gao, W. D., Dupuis, J., Latourelle, J. C., Zazueta, O. E., Fernandez, I. E., Nishino, M., Okajima, Y., et al. (2015) · BMC Pulmonary Medicine · doi:10.1186/s12890-015-0124-x · Cited by 58
Self-citationTargeted Therapy for Idiopathic Pulmonary Fibrosis: Where To Now?
Rangarajan, S., Locy, M. L., Luckhardt, T., & Thannickal, V. J. (2016) · Drugs · doi:10.1007/s40265-015-0523-6 · Cited by 56
Update on Pulmonary Fibrosis: Not All Fibrosis Is Created Equally
Smith, M. L. (2016) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2015-0288-sa · Cited by 52
Su, Y., Gu, H., Weng, D., Zhou, Y. Y., Li, Q., Zhang, F., Zhang, Y., Shen, L., Hu, Y., & Li, H. (2017) · Medicine · doi:10.1097/md.0000000000006617 · Cited by 48
Combination therapy in pulmonary arterial hypertension: recent accomplishments and future challenges
Lajoie, A., Bonnet, S., & Provencher, S. (2017) · Pulmonary Circulation · doi:10.1177/2045893217710639 · Cited by 58
Roach, K. M., Sutcliffe, A., Matthews, L., Elliott, G., Newby, C., Amrani, Y., & Bradding, P. (2018) · Scientific Reports · doi:10.1038/s41598-017-18555-9 · Cited by 50
A Real-Life Multicenter National Study on Nintedanib in Severe Idiopathic Pulmonary Fibrosis
Harari, S. A., Caminati, A., Poletti, V. E., Confalonieri, M., Gasparini, S., Lacedonia, D., Luppi, F., Pesci, A., Sebastiani, A., Spagnolo, P., et al. (2018) · Respiration · doi:10.1159/000487711 · Cited by 53
The Antifibrotic Activity of Prostacyclin Receptor Agonism Is Mediated through Inhibition of YAP/TAZ
Zmajkovicova, K., Menyhart, K., Bauer, Y., Studer, R. O., Renault, B., Schnoebelen, M., Bolinger, M., Nayler, O., & Gatfield, J. (2019) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2018-0142oc · Cited by 59
Translational research in pulmonary fibrosis
Mathai, S. K., & Schwartz, D. A. (2019) · Translational research · doi:10.1016/j.trsl.2019.02.001 · Cited by 53
Frailty and geriatric conditions in older patients with idiopathic pulmonary fibrosis
Sheth, J. S., Xia, M., Murray, S., Martinez, C. H., Meldrum, C. A., Belloli, E. A., Salisbury, M. L., White, E. S., Holtze, C. H., & Flaherty, K. R. (2019) · Respiratory Medicine · doi:10.1016/j.rmed.2019.01.008 · Cited by 53
Validation of the IPF-specific version of St. George’s Respiratory Questionnaire
Prior, T. S., Hoyer, N., Shaker, S. B., Davidsen, J. R., Yorke, J., Hilberg, O., & Bendstrup, E. M. (2019) · Respiratory Research · doi:10.1186/s12931-019-1169-9 · Cited by 58
Fois, A. G., Sotgiu, E., Scano, V., Negri, S., Mellino, S., Zinellu, E., Pirina, P., Pintus, G., Carru, C., Mangoni, A. A., et al. (2020) · Antioxidants · doi:10.3390/antiox9111064 · Cited by 56
“In 2014, the Food and Drug Administration approved nintedanib and pirfenidone for IPF treatment because of their ability to retard disease progression [14,15].”
BackgroundRiociguat for Sarcoidosis-Associated Pulmonary Hypertension
Baughman, R. P., Shlobin, O. A., Gupta, R., Engel, P. J., Stewart, J. I., Lower, E. E., Rahaghi, F., Zeigler, J., & Nathan, S. D. (2021) · CHEST Journal · doi:10.1016/j.chest.2021.07.2162 · Cited by 59
Self-citationSystematic Review and Network Meta-analysis of Idiopathic Pulmonary Fibrosis Treatments
Fleetwood, K., McCool, R., Glanville, J., Edwards, S. C., Gsteiger, S., Daigl, M., & Fisher, M. (2017) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2017.23.3-b.s5 · Cited by 49
Wang, Q., Li, W., Hu, H., Lu, X., & Qin, S. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114226 · Cited by 53
P38 kinase in gastrointestinal cancers
Phan, T. X., Zhang, X. H., Rosen, S. T., & Melstrom, L. G. (2023) · Cancer Gene Therapy · doi:10.1038/s41417-023-00622-1 · Cited by 59
The Idiopathic Pulmonary Fibrosis Clinical Research Network (IPFnet)
de Andrade, J. A., Schwarz, M. I., Collard, H. R., Gentry-Bumpass, T., Colby, T. V., Lynch, D. A., & Kaner, R. J. (2015) · CHEST Journal · doi:10.1378/chest.14-2889 · Cited by 54
Holland, A. E., Dowman, L., & Hill, C. J. (2015) · Respiration · doi:10.1159/000370126 · Cited by 53
Acute exacerbation of idiopathic pulmonary fibrosis: a clinical review
Luppi, F., Cerri, S., Taddei, S., Ferrara, G., & Cottin, V. (2015) · Internal and Emergency Medicine · doi:10.1007/s11739-015-1204-x · Cited by 56
“The number of AE-IPF or time to clinical worsening including AE-IPF was not significantly different between patients receiving pirfenidone or placebo in phase III trials, although pirfenidone significantly reduced the decline in FVC over time and improved survival at 1 year [64] [65] [66] .”
BackgroundMembrane-anchored Serine Protease Matriptase Is a Trigger of Pulmonary Fibrogenesis
Bardou, O., Menou, A., Francois, C., Duitman, J., von der Thüsen, J. H., Borie, R., Sales, K. U., Mutze, K., Castier, Y., Sage, É., et al. (2015) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201502-0299oc · Cited by 50
Normativa sobre el tratamiento farmacológico de la fibrosis pulmonar idiopática
Xaubet, A., Molina‐Molina, M., Acosta, O., Bollo, E., Castillo, D., Fernández‐Fabrellas, E., Rodríguez-Portal, J. A., Valenzuela, C., & Ancochea, J. (2017) · Archivos de Bronconeumología · doi:10.1016/j.arbres.2016.12.011 · Cited by 58
Smoking-associated interstitial lung disease: update and review
Dawod, Y., Cook, N. E., Graham, W. B., MADHANI-LOVELY, F. K., & Thao, C. (2020) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2020.1766971 · Cited by 55
Lung Involvement in Primary Sjögren's Syndrome—An Under-Diagnosed Entity
Sogkas, G., Hirsch, S., Olsson, K. M., Hinrichs, J. B., Thiele, T., Seeliger, T., Skripuletz, T., Schmidt, R. E., Witte, T., Dopfer‐Jablonka, A., et al. (2020) · Frontiers in Medicine · doi:10.3389/fmed.2020.00332 · Cited by 56
Supplemental Oxygen in Interstitial Lung Disease: An Art in Need of Science
Johannson, K. A., Pendharkar, S. R., Mathison, K., Fell, C. D., Guenette, J. A., Kalluri, M., Kolb, M. R. J., & Ryerson, C. J. (2017) · Annals of the American Thoracic Society · doi:10.1513/annalsats.201702-137oi · Cited by 56
Blood Transcriptomics Predicts Progression of Pulmonary Fibrosis and Associated Natural Killer Cells
Huang, Y., Oldham, J. M., Ma, S., Unterman, A., Liao, S.-Y., Barros, A. J., Bonham, C. A., Kim, J. S., Vij, R., Adegunsoye, A., et al. (2021) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202008-3093oc · Cited by 57
Merkt, W., Zhou, Y., Han, H., & Lagares, D. (2021) · Wound Repair and Regeneration · doi:10.1111/wrr.12952 · Cited by 71
“Up 147–149 Although these drugs slow down the rate of progression of fibrosis, they do not halt or reverse established fibrosis.”
The current landscape of antifibrotic therapy across different organs: A systematic approach
Fuster‐Martínez, I., & Calatayud, S. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107245 · Cited by 64
Black, K. E., Berdyshev, E. V., Bain, G., Castelino, F. V., Shea, B. S., Probst, C. K., Fontaine, B. A., Bronova, I. A., Goulet, L., Lagares, D., et al. (2016) · The FASEB Journal · doi:10.1096/fj.201500197r · Cited by 53
Preventive effects of vitamin D treatment on bleomycin-induced pulmonary fibrosis
Zhang, Z., Yu, X., Xia, F., Liang, A., Zhang, Y., Gu, P., Zeng, Y., He, J., Zhu, H., Li, S., et al. (2015) · Scientific Reports · doi:10.1038/srep17638 · Cited by 49
Metadata
- Authors
- King, T. E., Bradford, W. Z., Castro-Bernardini, S., Fagan, E. A., Glaspole, I., Glassberg, M. K., Gorina, E., Hopkins, P. M., Kardatzke, D., Lancaster, L., Lederer, D. J., Nathan, S. D., Pereira, C. A., Sahn, S. A., Sussman, R., Swigris, J. J., & Noble, P. W.
- Affiliations
- Cedars-Sinai Medical Center (US)
- The Alfred Hospital (AU)
- University of Miami (US)
- Prince Charles Hospital (AU)
- Vanderbilt University Medical Center (US)
- Columbia University Irving Medical Center (US)
- Inova Fairfax Hospital (US)
- Universidade Federal de São Paulo (BR)
- Medical University of South Carolina (US)
- Overlook Medical Center (US)
- National Jewish Health (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-05-29
- Volume
- 370
- Issue
- 22
- Pages
- 2083-2092
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2168666423
- Cited by
- 3,975
- References
- 27
- Citations by year
- 2026: 272 · 2025: 303 · 2024: 371 · 2023: 315 · 2022: 339 · 2021: 412 · 2020: 343 · 2019: 310 · 2018: 335 · 2017: 319 · 2016: 288 · 2015: 279 · 2014: 76
- FWCI
- 256.80
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- UNIFESP Institutional Repository (Universidade Federal de São Paulo) (submittedVersion)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Keywords
- pirfenidone, idiopathic pulmonary fibrosis, antifibrotic therapy, forced vital capacity decline, disease progression, mortality, progression-free survival, 6-minute walk distance, dyspnea, gastrointestinal adverse effects, cutaneous adverse events, exercise tolerance, lung function decline, safety and tolerability
- MeSH terms
- Administration, Oral, Adult, Aged, Aged, 80 and over, Antifibrinolytic Agents, Double-Blind Method, Enzyme Inhibitors, Female, Humans, Male, Middle Aged, Pyridones, Vital Capacity, Treatment Outcome, Disease Progression, Idiopathic Pulmonary Fibrosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.